Predicting the pathologic response of locally advanced rectal cancer to neoadjuvant concurrent chemoradiation using enzyme-linked immunosorbent assays (ELISAs) for biomarkers. [electronic resource]
Producer: 20140411Description: 399-409 p. digitalISSN:- 1432-1335
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Biomarkers, Tumor -- blood
- Carcinoembryonic Antigen -- blood
- Chemoradiotherapy, Adjuvant -- adverse effects
- Enzyme-Linked Immunosorbent Assay
- ErbB Receptors -- blood
- Female
- Humans
- Male
- Middle Aged
- Neoadjuvant Therapy -- methods
- Neoplasm Staging
- Predictive Value of Tests
- Prospective Studies
- Receptors, Urokinase Plasminogen Activator -- blood
- Rectal Neoplasms -- blood
- Tissue Inhibitor of Metalloproteinase-1 -- blood
- Treatment Outcome
- Vascular Endothelial Growth Factor A -- blood
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.